{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-284579","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.752713+00:00","generated_at":"2026-06-21T20:39:51.106284+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spero Therapeutics Q3 net loss narrows to $11.7M; secures $75M from GSK license and equity investment","bullets":["Net loss $11.7M ($0.33/shr) vs $22.5M ($0.70/shr) in Q3 2021; revenue $2M down from $3.1M.","Cash $50.4M at Sep 30; post-Q3 received $9M GSK equity, $66M upfront invoiced; runway extended beyond 2024.","GSK license for tebipenem HBr closed; $66M upfront, $9M equity, up to $525M milestones plus tiered royalties.","SPR720 Phase 2 trial initiated for NTM pulmonary disease; top line data expected 1H 2024.","Kamal Hamed joined as CMO in Sep 2022; received inducement awards of 210k RSUs and 140k PSUs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-284579","json":"https://secwatch.observer/filing/0001193125-22-284579.json","markdown":"https://secwatch.observer/filing/0001193125-22-284579.md","text":"https://secwatch.observer/filing/0001193125-22-284579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/0001193125-22-284579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/d189186d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:39:51.106284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ceb8e9ff358d59903214c3c8f87424a959905727","claim":"Spero Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.","evidence_excerpt":"On November 14, 2022, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312522284579/0001193125-22-284579-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}